Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NextEra Energy

Visa

American Water Works

Canadian National Railway Company

Each of these companies has serious potential to bring profits to investors, especially those with long time horizons.

5 Great Stocks You Can Buy and Hold Forever

J&J to resume U.S. part of COVID-19 vaccine clinical trial

Moderna

Pfizer

President Trump said a coronavirus vaccine is weeks away in his first remarks during Thursday's presidential debate.

COVID-19 vaccine weeks away, J&J, Moderna, Pfizer leading race

NEW BRUNSWICK, N.J., Oct. 22, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2020 of $1.01 per share on the company's common stock. The dividend is payable on December 8, 2020 to...

Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2020

AstraZeneca

Clinical studies on coronavirus vaccine candidates of AstraZeneca (AZN) and J&J (JNJ) which were paused for reviewing adverse events are anticipated to resume as early as this week.

AstraZeneca (AZN), J&J (JNJ) Coronavirus Trials May Resume Soon

Biogen

BYD Company Limited

Systemic difference had led to divergence in control of COVID-19 cases in major economies which should be reflected in our portfolio. Warren Buffett had shown the way by his investment into electric vehicles and pharmaceutical companies.

Finding The Buffett Balance For Your Portfolio As Major Economies Diverge

U.S. phase 3 studies for AstraZeneca's and Johnson & Johnson's coronavirus vaccines still haven't resumed. Should investors be worried?

2 Late-Stage Coronavirus Vaccine Candidates in Limbo

Ciena

Slack

These three transformative stocks can build a diversified portfolio in an instant.

Now Is the Time to Go All-In on These 3 Breakout Stocks

Colgate-Palmolive

Coca-Cola

Altria

Procter & Gamble

The true definition of dividend growth investing is quite clear, but I am finding plenty of folks here really do not understand it.

Retirement Strategy: What Does Dividend Growth Investing Actually Mean?

Carlisle Companies

Sanofi

4 Blue Chips To Sleep Well At Night In These Uncertain Times

Caterpillar

Cisco Systems

Channeladvisor

Honeywell

Intel

McDonald's

Merck

NIKE

Pluristem Therapeutics

Walmart

Two new sample breakout stocks for Week 43 with better than 10% short-term upside potential. Now up an average +241.2% YTD.

Week 43 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

Costco

General Dynamics

Lockheed Martin

Medtronic

PepsiCo

10 Dividend Growth Stocks For October 2020

These two pharma heavyweights are among the many players racing to get a COVID-19 vaccine approved.

Better Coronavirus Stock: AstraZeneca or Johnson & Johnson

BioNTech SE

Inovio Pharmaceuticals

Novavax

Two programs may seek emergency use authorization within the next six weeks.

What You Need to Know at This Stage of the Coronavirus Vaccine Race

It appears shares of Johnson & Johnson (NYSE:JNJ) were dragged down earlier in the week at least in part over news that the New Jersey-based pharmaceutical giant had to pause trials for its Covid-19 vaccine after a volunteer got sick.

Look Past Covid Vaccine to Johnson & Johnson's Drug Portfolio

Bank of America

JPMorgan Chase & Co

Microsoft

AT&T

Verizon

Exxon Mobil

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Seeking Alpha recently published a list of the 10 most popular dividend stocks on the platform.

10 Most Popular Dividends Stocks: 4 To Buy, 2 To Hold, 4 To Avoid

Johnson & Johnson (NYSE:JNJ) has had a mixed quarter this time around. While its results were strong with demonstrated growth in many of its key pharmaceutical products, the medical devices segment continues its struggle.

Johnson & Johnson: The Good, the Bad and the Ugly

Learn about the origins of Johnson & Johnson and the health care conglomerate's five largest shareholders.

The Top 5 Johnson & Johnson Shareholders (JNJ)

ALPS Barron's 400 ETF

Trns DS S&P 500 Shs

iShares Core High Dividend ETF

Volatility has once again been playing foul in the stock market due to resurgent COVID-19 infections and fading hopes of additional stimulus. Investors should follow some techniques to minimize volatility in their portfolio.

News for Johnson & Johnson Stock (JNJ)